title: Adjuvant systemic therapies in women with breast cancer: an audit of clinical practice in Italy.
abstract: BACKGROUND
  Evidence-based guidelines, consensus conferences and experts' opinion are rarely promptly transferred to patient care. We audited prescriptions of adjuvant systemic therapies for Italian breast cancer patients and compared them with recommendations of an International Consensus Panel.
  
  
  METHODS
  Disease characteristics and adjuvant therapies for 768 breast cancer patients referred to 87 Italian centers from 16 to 23 March 2000 were evaluated for adherence to the published recommendations.
  
  
  RESULTS
  Endocrine therapy was not prescribed for 102 of 541 patients (19%) with endocrine-responsive disease and for 22 of 45 patients (49%) with unknown hormonal receptor status. Instead, endocrine therapy was prescribed for 22 of 182 patients (12%) with endocrine-unresponsive disease. Adjuvant chemotherapy was prescribed for 98% of the patients. The type of chemotherapy was the cyclophosphamide, methotrexate, 5-fluorouracil regimen for 453 of 754 (60%), while 253 of 754 (34%) received an anthracycline-based regimen. The proportion of patients with anthracyclines increased with the number of involved axillary nodes and grading, and decreased with age. Endocrine therapy was administered to 482 of 768 (63%) and was mainly represented by an antiestrogen.
  
  
  CONCLUSIONS
  Lack of adherence to evidence-based guidelines for adjuvant treatment of Italian breast cancer patients was as high as 19%. It might be wise for national health authorities to promote education on life-saving procedures, like adjuvant systemic treatments, in cancer medicine.
authors.affiliation: Divisione Oncologia Medica, Ospedale Policlinico, Perugia, Italy. faroila@unipg.it
authors.forename: F
authors.initials: F
authors.lastname: Roila
authors.forename: E
authors.initials: E
authors.lastname: Ballatori
authors.forename: L
authors.initials: L
authors.lastname: Patoia
authors.forename: S
authors.initials: S
authors.lastname: Palazzo
authors.forename: A
authors.initials: A
authors.lastname: Veronesi
authors.forename: A
authors.initials: A
authors.lastname: Frassoldati
authors.forename: G
authors.initials: G
authors.lastname: Cetto
authors.forename: S
authors.initials: S
authors.lastname: Cinieri
authors.forename: A
authors.initials: A
authors.lastname: Goldhirsch
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017024:Chemotherapy, Adjuvant; D011307:Drug Prescriptions / Q000706:statistics & numerical data; D017723:Drug Utilization Review; D019317:Evidence-Based Medicine; D005260:Female; D019983:Guideline Adherence / Q000706:statistics & numerical data*; D020249:Hormone Replacement Therapy; D006801:Humans; D007558:Italy; D008485:Medical Audit; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D012307:Risk Factors
chemical_list: D011960:Receptors, Estrogen; D011980:Receptors, Progesterone